ArticleUrolithiasis2026
Moroccan Pinus pinaster bark as a dual in vivo and in silico nephroprotective agent against nephrocalcinosis: toxicity and ADMET insights.
Article in Urolithiasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pinus pinaster Aiton, commonly known as maritime pine, is extensively utilized in traditional Mediterranean medicine for a variety of ailments, particularly renal dysfunctions. Its bark is notably high in polyphenols, which may possess therapeutic properties. This study aimed to assess the protective effects of a hydroalcoholic bark extract from P. pinaster (PPBE) against nephrocalcinosis induced by ethylene glycol (EG) in rats, supplemented by in silico toxicity and ADMET profiling. Nephrocalcinosis was induced by providing rats with EG in their drinking water for 30 days, during which they were administered daily doses of either PPBE or cystone. We analyzed urinary parameters (volume, pH, electrolytes), conducted serum biochemical assessments, and measured creatinine clearance. Renal histopathology was performed to evaluate tissue changes. In silico studies were carried out on the main phytoconstituents to predict their toxicity and pharmacokinetics. The EG-treated rats exhibited significant urinary and biochemical alterations, including decreased urine output, pH, and electrolyte excretion, coupled with elevated serum creatinine and urea levels. Notably, treatment with PPBE (200 mg/kg) significantly boosted urine volume from 6 ± 1 ml to 12 ± 1 ml (p < 0.001), enhanced creatinine clearance (0.44 ± 0.09 ml/min), reduced urinary calcium and phosphate levels, and increased magnesium levels when compared to the EG group. Histopathological evaluations confirmed renal protection in the treated groups. In silico analyses revealed favorable ADMET properties and low toxicity predictions for key constituents, particularly catechin and proanthocyanidin. Overall, PPBE demonstrates protective effects against nephrocalcinosis by restoring urinary and biochemical equilibrium, inhibiting crystal formation, and safeguarding renal tissue. The integration of in vivo and in silico findings highlights its therapeutic potential and pinpoints promising bioactive candidates for future research.
Indexed as
Identifiers
41543741What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.